The generic drug manufacturer recently required to repay covered entities for charging above the ceiling price following an audit has posted a notice on the U.S. Health Services and Resources Administration (HRSA) website about recalculation of ceiling prices and “potential payment” of “eligible refunds.”
The notice, dated Jan. 25, was posted by Beach Products Inc. and does not address the audit. Pharmaceutical Associates Inc. (PAI) was the manufacturer that HRSA audited. A company contact listed on both the PAI audit results webpage and the Beach notice to covered entities is the same person with the same Beach email address.
The generic drug manufacturer recently required to repay covered entities for charging above the ceiling price following an audit has posted a notice on the U.S. Health Services and Resources Administration (HRSA) website about recalculation of ceiling prices and “potential payment” of “eligible refunds.”
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
